A

Abbott

Makes heart devices, glucose sensors and lab tests

Principal Field Clinical Procedure Specialist

Full-Time
$99.3k - $198.7k
Senior
Bachelor's, Master's
Remote in USA
RemoteRemote within the United States; travel 50–60%+, including possible international travel.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A B.S. degree, preferably in technical science or another related field such as Nursing, a Master degree, or an equivalent combination of education and work experience.
  • Seven years of experience working with healthcare professionals in clinical research, clinical case support, or commercial case support.
  • Experience in Cardiac Rhythm Management is preferred.
  • Medical device experience is preferred.
  • Experience supporting clinical cases in a hospital environment is preferred.
  • Ability to communicate effectively and professionally in a hospital environment is preferred.
  • Understanding and application of business concepts, procedures, and practices are preferred.
  • Demonstrated leadership skills in achieving company goals and objectives are preferred.
  • Ability to work in a highly matrixed and geographically diverse business environment is preferred.
  • Ability to work within a team and as an individual contributor in a fast-paced, changing environment is preferred.
  • Ability to leverage or engage others to accomplish projects is preferred.
  • Strong verbal, written communication, and interpersonal skills, including the ability to communicate effectively at multiple organizational levels, are preferred.
  • Willingness and ability to travel 50–60% or more, including international travel, is preferred.
Responsibilities
  • Develop and maintain liaison with clinical investigators, medical educators, clinical research organizations, affiliated hospitals, state or government hospitals, and research institutions to initiate and expedite clinical studies on products with investigational new drug or medical device approval.
  • Assist with post-procedure follow-ups as necessary.
  • Review adverse event cases with investigators, determine and monitor schedules, prepare study documents, issue status reports, and report adverse events to appropriate clinical and regulatory personnel at Abbott.
  • Assist with the design, development, and monitoring of clinical evaluation projects as needed.
  • Train investigators and site personnel on relevant procedural and technical considerations.
  • Support headquarter and field clinical research associates.
  • Contact and recommend qualified investigators to perform studies and initiate clinical trials as needed.
  • Ensure recruitment and retention of patients.
  • Advise on appropriate study enrollment based on protocol inclusion and exclusion criteria.
Desired Qualifications
  • Experience in Cardiac Rhythm Management.
  • Medical device experience.
  • Experience supporting clinical cases in a hospital environment.
  • Ability to communicate effectively and professionally in a hospital environment.
  • Understanding and application of business concepts, procedures, and practices.
  • Demonstrated leadership skills in achieving company goals and objectives.
  • Ability to work in a highly matrixed and geographically diverse business environment.
  • Ability to work within a team and as an individual contributor in a fast-paced, changing environment.
  • Ability to leverage or engage others to accomplish projects.
  • Strong verbal, written communication, and interpersonal skills, including the ability to communicate effectively at multiple organizational levels.
  • Willingness and ability to travel 50–60% or more, including international travel.

About the company

A

Abbott

View
Website

Abbott makes medical devices, diagnostic tests, nutrition products and branded generic drugs for hospitals, laboratories, pharmacies and patients. Its best-known product is the FreeStyle Libre, a coin-sized sensor worn on the upper arm that tracks blood sugar around the clock without routine finger pricks. Its other lines run from heart valves, pacemakers and brain stimulators to lab analyzers, rapid tests and mail-in colon cancer screening kits, and Abbott earns money by selling these products to health systems, labs, retailers and consumers. The company was founded in 1888 by Chicago physician Wallace Abbott and is based in Abbott Park, Illinois.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to Abbott

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Devices carry the growth: Abbott's device sales rose 8.4% on a comparable basis from April to June 2026.
  • Diabetes teams get a launch to build: FDA authorized Libre Duo, the first glucose and ketone sensor, in August 2026.
  • Abbott bought a cancer screening business: its roughly $21 billion Exact Sciences purchase closed in March 2026.

What critics are saying

  • Formula lawsuits linger: after a $670 million August 2026 settlement, about 1,700 suits over preemie formula remain.
  • Nutrition staff sit in a shrinking unit: Abbott's nutrition sales fell 3.6% comparably from April to June 2026.
  • Abbott's top product drew a severe recall: FDA flagged Libre 3 sensor errors linked to seven deaths in January 2026.

What makes Abbott unique

  • Abbott's drug arm skips the US: it sells branded generic medicines only in markets such as India and Latin America.
  • Abbott sells to grocery shoppers too: Similac formula and Ensure shakes sit on store shelves, unlike device rivals.
  • Abbott's heart implant reports to patients: CardioMEMS lets heart failure patients read their own artery pressure on phones.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Professional Development Budget
  • Wellness Program

Growth & Insights and Company News

6 month growth

-6%

1 year growth

5%

2 year growth

5%
DrugDu
Oct 26th, 2026
Another global medical device giant has officially announced its spin-off!

Another global medical device giant has officially announced its spin-off! October 26, 2026 Source: drugdu 43 According to recent foreign media reports, Abbott announced the spin-off of its businesses and a downward revision of its full-year guidance after releasing its Q3 results. Abbott announced plans to spin off its nutrition business into an independent company by the end of 2027. The new independent company will have annual sales of $8.5 billion, 16,000 employees, and 14 manufacturing sites. Its product portfolio will include well-known brands such as Ensure (a nutritional supplement drink), PediaSure (a pediatric nutritional supplement), Glucerna (a diabetes management nutrition brand), and Similac (an infant formula brand). Daniel Salvadori, the current Executive Vice President and Group President of Mature Pharmaceuticals and Nutrition Products, will become the CEO of this independent company. The spin-off plan includes Abbott distributing shares of the independent nutrition company to Abbott shareholders. Upon completion of the spin-off, Abbott shareholders will hold shares in both Abbott and the independent nutrition company. It is worth mentioning that before the spin-off plan was announced, Abbott had already reached settlement agreements worth more than $1 billion in lawsuits related to its infant formula products - of which $670 million was used to settle 2,000 claims and nearly $385 million was used to resolve charges related to the U.S. Department of Justice's False Declarations Act. However, the spin-offs by these giants are not a contraction, but a refocusing. Undoubtedly, they are divesting non-core, low-growth segments, channeling the resulting cash flow and organizational energy into higher-certainty battlegrounds. Abbott is no exception. After the spin-off, Abbott will focus on its core high-growth, innovation-driven portfolio of medical devices, diagnostics, and established pharmaceuticals. The spun-off nutrition business can also operate as an independent company, allowing for better allocation of strategic resources and a focus on priorities. Looking at Abbott's Q3 results, the spin-off plan has become clearer. In Q3, Abbott achieved revenue of $13.013 billion (+14.5%) and net profit of $920 million, a year-on-year decrease of 44.01%. Within Abbott's business segments, medical devices and established pharmaceuticals are the two main revenue drivers. In Q3, medical device sales grew 6.9% to $5.826 billion. Electrophysiology and cardiac rhythm management saw significant growth, both achieving double-digit increases. However, the nutrition business experienced slower growth and smaller scale compared to other segments, with revenue of $2.262 billion this quarter, representing a year-over-year increase of only 5.1%. At the same time, Abbott lowered its full-year guidance to comparable sales growth of 6.0% and earnings per share of $5.50 to $5.55, down from its previous guidance of sales growth of 6.5% to 7.5% and earnings per share of $5.45 to $5.60. It's worth noting that global medical device giants have frequently spun off their businesses in recent years. Following Medtronic's spin-off of MiniMed and Johnson & Johnson's proposed spin-off of its orthopedic business, DePuy Synthes, Abbott also officially announced the spin-off of its nutrition business into an independent company. Furthermore, business restructuring has been frequently occurring in the past two years. GE Healthcare integrated its imaging business and advanced visualization solutions into the "Advanced Imaging Solutions (AIS)" segment, while simultaneously promoting Patient Care Solutions (PCS) to improve profitability and evaluate its strategic options. Boston Scientific has launched a new round of global restructuring, involving supply chain optimization, production line relocation, and organizational restructuring, which is expected to be largely completed by the end of 2029. Source: https://news.yaozh.com/archive/49226.html

PR Newswire
Oct 23rd, 2026
Abbott's whole-genome Oncodetect test boosts colorectal cancer recurrence detection sensitivity by 30%

Abbott said its whole-genome sequencing Oncodetect test detected colorectal cancer recurrence far more often than the whole-exome version. New Beta-CORRECT data presented at the European Society for Medical Oncology Congress showed a 30-percent absolute improvement in sensitivity within two years of surgery, using a single post-surgery blood draw. The test reached 72.2% sensitivity, against 42.2% for the earlier test. Among 157 patients tested with both, it found circulating tumour DNA (ctDNA) in all 29 patients the older test caught, plus 15 more. Patients with detectable ctDNA after surgery had a 10.6-fold higher risk of recurrence. Two-year disease-free survival was 36.2%, versus 92.3% for ctDNA-negative patients. The study analysed samples from 279 patients, mostly with stage II and III disease. The test tracks up to 5,000 DNA variants unique to each tumour.

Arab Health Media Communication
Oct 23rd, 2026
Mubadala Bio and Abbott collaborate to advance pharmaceutical manufacturing in the UAE.

Mubadala Bio and Abbott collaborate to advance pharmaceutical manufacturing in the UAE. Less than a minute Mubadala Bio and Abbott announced a strategic collaboration during the Abu Dhabi Future Health Summit aimed at supporting local pharmaceutical manufacturing initiatives and contributing to the continued development of the UAE's healthcare ecosystem. The collaboration brings together Mubadala Bio's local manufacturing capabilities and Abbott's longstanding commitment to expanding access to high-quality medicines, with the shared goal of supporting healthcare delivery and advancing pharmaceutical capabilities in the UAE. As part of the collaboration, Abbott and Bioventure Healthcare FZE, a Mubadala Bio company, signed a local manufacturing agreement focused on women's health therapies. The companies are exploring potential future areas of collaboration, including vaccines and biosimilars. Any future collaboration would be subject to further assessment and execution of definitive agreements.

Just Food
Oct 22nd, 2026
India regulator pulls up Nestlé, Abbott over infant-formula violations.

India regulator pulls up Nestlé, Abbott over infant-formula violations. The FSSAI issued a notice to Nestlé India concerning its Lactogen Pro 1 Powder, seeking scientific substantiation for whey protein claims. India's food-safety watchdog has issued notices to the local units of Nestlé and Abbott Laboratories over claims and promotions relating to infant formula. The Food Safety and Standards Authority of India (FSSAI) issued a notice yesterday (21 October) to Nestlé India concerning its Lactogen Pro 1 Powder, seeking scientific substantiation for claims the product "contains whey protein, which is a part of milk protein that is easy to digest". A separate notice concerning Nestlé's NAN Excella Pro Stage 1 questioned the claim that "5 HMOs helps support normal immune system". The regulator said the wording could "imply that the product is suitable for supporting the immune system, suggesting its use in relation to a particular physiological condition". "The claim was considered non-compliant with provisions prohibiting claims relating to the prevention, alleviation, treatment or cure of any disease, disorder or particular physiological condition, unless specifically permitted under applicable regulations," the FSSAI observed. Consequently, Nestlé India was directed to explain why action should not be initiated under the Food Safety and Standards Act 2006, and related rules and regulations. The post featured a "Top 5" list of infant-formula products, including Abbott's Similac Advance 1, Nutricia International's Aptamil Premium 1 and Dexolac 1, Nestlé India's Nan-Pro 1, and Reckitt Benckiser-owned Mead Johnson Nutrition's Enfamil A+ Stage 1. According to the FSSAI, the promotional video breached the Infant Milk Substitutes Act and infant nutrition marketing regulations by attributing benefits such as "balanced nutrition, stronger immunity, brain development and easy digestion to the products". Responding to the notice, Abbott told Just Food it was not involved in the post, had no relationship with the creator, and only became aware of the video after receiving the regulator's notice. "The content was independently created and published by a third party without Abbott's knowledge, involvement or authorisation," the group said, adding that it had communicated the fact to the FSSAI and does not endorse the representations made in the video. The measures form part of a widening FSSAI crackdown on nutritional marketing. In parallel, the regulator issued a so-called show-cause notice to Zydus Wellness Products over claims made on its Complan brand, including "2X Faster Growth", "Supports Concentration and Memory", and "Pro Immunity+ 34 Vital Nutrients". The authority demanded scientific justification for claims that Complan is "clinically proven" to help children grow taller faster, and cited the marketing slogan "Growth Comes in 4 Flavors" as non-compliant with advertising rules. The latest enforcement follows allegations by the regulator that the local arms of Nestlé and Unilever had made "misleading" health claims on adult and maternal nutrition lines. In those cases, Nestlé faced regulatory scrutiny over claims made for its Resource Renal vanilla-flavour powder, marketed for people with chronic kidney disease, while Hindustan Unilever (HUL), the UK-based FMCG group's local listed business, was issued notices on two Horlicks products. Just Food has contacted Mead Johnson Nutrition, Nestlé, Nutricia International, and Zydus Wellness Products in India for comment on the latest notices. Give your business an edge with its leading industry insights.

Telangana Today
Oct 22nd, 2026
FSSAI notices put baby food and nutrition product claims under scrutiny.

FSSAI notices put baby food and nutrition product claims under scrutiny. FSSAI has issued show-cause notices to major food and nutrition companies over claims made for infant formula and children's nutritional drinks. The regulator has sought scientific evidence and explanations, while also questioning the promotion of infant formula products on social media. Published Date - 22 October 2026, 06:10 PM Hyderabad: Wrapping commercial products in scientific-sounding jargon, emotionally playing on parental anxieties to coax them into buying baby food, and pushing unverified health claims to boost sales of health and baby products has, for a long time, been a standard playbook for companies. However, such deceptive and misleading claims are finally being met with resistance, as food regulators and apex courts have started insisting that before flooding the markets with their untested products, MNCs and nutritional giants must prove what they claim in the laboratory first. The recent wave of show-cause notices to Nestle, Abbott, Mead Johnson Nutrition and Zydus, by the Food Safety and Standards Authority of India (FSSAI), against such deceptive advertisements, unverified health claims and promotional violations, has put a spotlight back on the practice of misleading vulnerable consumers and making profit at their cost. The FSSAI action has come in the wake of the Supreme Court's scathing remarks over deceptive advertising and public health safety. The apex court slammed companies that make misleading claims and even hauled up regulators for dragging their feet on clear front-of-pack warning labels, questioning whether undue pressure from powerful food manufacturers has allowed public health interests to be sidelined. The food regulator notices have also made it clear that companies can no longer treat clinical trials as marketing tools. From now on, any claim of enhanced growth due to a product or claims that a specific additive will make a baby's brain grow smarter or better will have to undergo rigorous peer-reviewed scientific scrutiny evaluated directly by regulatory authorities. The authorities have also included social media influencers and digital content creators in regulatory warnings to address a major loophole. In the last few years, such influencers and content creators, through promotional reels and unboxing videos, casually recommend specific baby milk substitutes under the guise of lifestyle advice. Such claims made by influencers are now firmly in the crosshairs of regulatory agencies. Public health specialists familiar with the issue said that FSSAI warnings to big brands over fake health claims on drinks, baby formula, and social media advertisements show that much of the industry relies on guesswork and claims, not on hard facts. Infant Nutrition - Companies rely on scientific jargon, unverified health claims, and parental anxieties to boost sales - Food regulators and the Supreme Court are demanding that nutritional giants prove their claims in the lab before launching products - FSSAI has issued show-cause notices to Nestle, Abbott, Mead Johnson Nutrition, and Zydus over deceptive ads and promotional violations - Companies can no longer use clinical trials as marketing tools - Physical growth and brain-development claims must face rigorous peer-reviewed scrutiny - Regulatory warnings to influencers and content creators who casually push baby milk substitutes under the guise of lifestyle advice - Crackdown exposes an industry built on guesswork and unverified claims rather than hard data * Follow Us: Discover more Try New Foods